Bifunctional BTK Degrading Compounds Via Ubiquitin Proteasome Pathway
Summary
The European Patent Office published patent EP3924350A1, granted to Nurix Therapeutics, Inc., covering bifunctional compounds for degrading BTK via the ubiquitin proteasome pathway. The patent application includes six IPC classifications spanning pharmaceutical compositions and therapeutic methods. Protection extends across 31 designated European states including major markets.
What changed
The European Patent Office granted patent EP3924350A1 to Nurix Therapeutics, Inc., covering bifunctional compounds designed to degrade Bruton's tyrosine kinase (BTK) through the ubiquitin proteasome pathway. Six inventors are credited: KATO, Daisuke; KONST, Zef; MIHALIC, Jeffrey; ROBBINS, Daniel W.; and SANDS, Arthur T. The patent is classified under pharmaceutical composition and therapeutic method categories.
Affected parties include the patent holder (gains exclusive rights to the technology in designated states) and potential licensees or competitors in the BTK degradation therapeutic space. The patent confers enforceable intellectual property rights but does not impose regulatory compliance obligations on third parties.
Archived snapshot
Apr 18, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY
Publication EP3924350A1 Kind: A1 Apr 08, 2026
Applicants
Nurix Therapeutics, Inc.
Inventors
KATO, Daisuke, KONST, Zef, MIHALIC, Jeffrey, ROBBINS, Daniel, W., SANDS, Arthur, T.
IPC Classifications
C07D 403/04 20060101AFI20200821BHEP C07D 403/14 20060101ALI20200821BHEP C07D 417/04 20060101ALI20200821BHEP C07D 417/14 20060101ALI20200821BHEP A61K 31/497 20060101ALI20200821BHEP A61P 35/00 20060101ALI20200821BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.